Legal Representation
Attorney
Christian S. Morgan
USPTO Deadlines
Application History
50 events| Date | Code | Type | Description |
|---|---|---|---|
| Apr 10, 2023 | ABN6 | S | ABANDONMENT - NO USE STATEMENT FILED |
| Apr 10, 2023 | MAB6 | E | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED |
| Sep 7, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sep 6, 2022 | EX5G | S | SOU EXTENSION 5 GRANTED |
| Sep 1, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Sep 1, 2022 | EXT5 | S | SOU EXTENSION 5 FILED |
| Jun 3, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Jun 3, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Jun 3, 2022 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS |
| Jun 3, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED |
| Feb 12, 2022 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 10, 2022 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 10, 2022 | EXT4 | S | SOU EXTENSION 4 FILED |
| Feb 10, 2022 | EX4G | S | SOU EXTENSION 4 GRANTED |
| Nov 3, 2021 | DOCK | D | ASSIGNED TO EXAMINER |
| Sep 21, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Sep 20, 2021 | EX3G | S | SOU EXTENSION 3 GRANTED |
| Sep 17, 2021 | PROA | I | TEAS PETITION TO REVIVE RECEIVED |
| Sep 17, 2021 | PETG | O | PETITION TO REVIVE-GRANTED |
| Sep 17, 2021 | TPEX | I | SOU EXTENSION RECEIVED WITH TEAS PETITION |
| Sep 17, 2021 | NREV | E | NOTICE OF REVIVAL - E-MAILED |
| Sep 10, 2021 | EXT3 | S | SOU EXTENSION 3 FILED |
| Feb 23, 2021 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Feb 19, 2021 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Feb 19, 2021 | EXT2 | S | SOU EXTENSION 2 FILED |
| Feb 19, 2021 | EX2G | S | SOU EXTENSION 2 GRANTED |
| Aug 14, 2020 | EXRA | E | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED |
| Aug 12, 2020 | EEXT | I | SOU TEAS EXTENSION RECEIVED |
| Aug 12, 2020 | EXT1 | S | SOU EXTENSION 1 FILED |
| Aug 12, 2020 | EX1G | S | SOU EXTENSION 1 GRANTED |
| Mar 10, 2020 | NOAM | E | NOA E-MAILED - SOU REQUIRED FROM APPLICANT |
| Jan 14, 2020 | PUBO | A | PUBLISHED FOR OPPOSITION |
| Jan 14, 2020 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Dec 25, 2019 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Dec 11, 2019 | ALIE | A | ASSIGNED TO LIE |
| Dec 6, 2019 | CNSA | P | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Nov 6, 2019 | CNEA | R | EXAMINERS AMENDMENT -WRITTEN |
| Nov 6, 2019 | GNEA | O | EXAMINERS AMENDMENT E-MAILED |
| Nov 6, 2019 | GNEN | O | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Nov 6, 2019 | XAEC | I | EXAMINER'S AMENDMENT ENTERED |
| Jun 17, 2019 | CNFR | R | FINAL REFUSAL WRITTEN |
| Jun 17, 2019 | GNFR | O | FINAL REFUSAL E-MAILED |
| Jun 17, 2019 | GNFN | O | NOTIFICATION OF FINAL REFUSAL EMAILED |
| Jun 13, 2019 | MDSM | E | NOTICE OF DESIGN SEARCH CODE E-MAILED |
| Jun 12, 2019 | AITU | A | CASE ASSIGNED TO INTENT TO USE PARALEGAL |
| Jun 12, 2019 | DPCC | D | DIVISIONAL PROCESSING COMPLETE |
| Apr 22, 2019 | ERTD | I | TEAS REQUEST TO DIVIDE RECEIVED |
| Apr 22, 2019 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Apr 22, 2019 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Apr 22, 2019 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED |
Detailed Classifications
Class 010
Medical apparatus for detecting and treating for the treatment of type2 diabetes mellitus, metabolic syndrome, bladder disorder, gastroesophageal reflex disease, fecal incontinence, glaucoma, cancer, cognitive impairment associated with schizophrenia, ophthalmology, arrhythmia and bile duct and diagnostic imaging
First Use Anywhere:
0
First Use in Commerce:
0
Class 041
Instruction in the field of dosage management; entertainment services, namely, providing online computer games; providing therapeutic exercise instruction; sports club services, namely, physical fitness instruction
First Use Anywhere:
0
First Use in Commerce:
0
Class 044
Medical service, medical diagnostic testing services, surgery support services related to medical care for type2 diabetes mellitus, metabolic syndrome, bladder disorder, gastroesophageal reflex disease, fecal incontinence, glaucoma, cancer, cognitive impairment associated with schizophrenia, ophthalmology, arrhythmia and bile duct
First Use Anywhere:
0
First Use in Commerce:
0
Additional Information
Design Mark
The mark consists of the letters "R" and "X" and a plus sign.
Color Claim
Color is not claimed as a feature of the mark.
Pseudo Mark
R X PLUS
Classification
International Classes
010
041
044
Disclaimers
The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"RX"